Key strategies for overcoming common hurdles in ALS clinical trials

Click here to subscribe to Fiercebiotech.com

2 years ago

Html
Text

This week's Fierce Biotech is brought to you by IQVIA.
Trouble viewing? Click here.

Solutions for you to drive healthcare forward™

Mitigating Trial Risk in ALS Clinical Development

Key strategies for overcoming common hurdles in ALS research

The development of new treatments has been slow, with only two approved disease-modifying drugs that offer limited benefit. But significant advances in immuno-neurology have set the stage for promising novel treatments that could offer hope to these families and change the course of this disease.
IQVIA has been at the leading edge of this research. Our experts have identified key strategies for overcoming common hurdles and strengthening patient centricity in ALS research, and for driving new progress that can benefit ALS patients across the globe.

4820 Emperor Boulevard, Durham, NC 27703, USA

Information provided by you may be collected and automatically stored in our database and may be used for sending you additional information about IQVIA and our services. Such information also may be transferred to IQVIA companies in other countries.
© 2022. All rights reserved. IQVIA is a registered trademark of IQVIA Inc. in the United States, the European Union, and various other countries.

If you no longer wish to receive communications from IQVIA, please opt out here.

Want to reach 137,000+ Fierce Biotech subscribers with your own message?
Contact aalcover@questex.comor call 202-824-5074.

You are currently subscribed as newsletter@newslettercollector.com.
If you no longer wish to receive communications from Fierce Biotech's trusted partners, simply click here to unsubscribe.
Refer to our Privacy Policy.

Questex, LLC
685 3rd Avenue, 21st Floor
New York, NY 10017

Share on

Other newsletters from Fiercebiotech.com

| 11.25.24 | Cassava ends Alzheimer’s trial after ph .3 flop; Biohaven plots obesity pivot after SMA fail Fiercebiotech.com
an hour ago
Optimizing Your Patient Support Strategy with Hub Model Innovation Fiercebiotech.com
2 hours ago
| 11.23.24 | House passes sweeping nonprofits bill; Trump taps Dr. Oz to run CMS Fiercebiotech.com
Last Saturday at 13:32

More newsletters from Fiercebiotech.com

Key strategies for overcoming common hurdles in ALS clinical trials

Mitigating Trial Risk in ALS Clinical Development

Key strategies for overcoming common hurdles in ALS research

Share on

Other newsletters from Fiercebiotech.com

Related newsletters